WGS

MKT CAP:$2B

GeneDx Holdings Corp.

Market Cap

$2B

Healthcare·Medical - Healthcare Information Services·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$66.24-$66.06 (-49.93%)

Apr 23, 2026

Company Details

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human ...

CEO

Katherine A. Stueland

IPO Date

Nov 4, 2020

Website

www.genedx.com

Key Metrics TTM

Revenue

$428M

+40.0% YoY

Net Income

-$21M

EPS (Diluted)

-$0.73

Free Cash Flow

$14M

Revenue / Share

$15.90

Gross Margin

68.5%

Operating Margin

-2.9%

Net Margin

-4.9%

FCF Margin

3.3%

P/S

4.7x

P/E

—

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

FY 2025

Feb 23, 2026

$428M+40.0%EPS -$0.73

Q4 2025

Feb 23, 2026

$121M+26.5%EPS -$0.59

Q3 2025

Oct 28, 2025

$117M+51.9%EPS -$0.27

Q2 2025

Jul 29, 2025

$103M+45.6%EPS $0.36

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$54M	$6M	-$89M
Q2 22	$36M	-$30M	-$163M
Q3 22	$83M	$14M	-$91M
Q4 22	$61M	-$16M	-$325M
Q1 23	$43M	$15M	-$60M
Q2 23	$49M	$19M	-$52M
Q3 23	$53M	$25M	-$43M
Q4 23	$57M	$31M	-$26M
Q1 24	$62M	$37M	-$14M
Q2 24	$71M	$43M	-$11M
Q3 24	$77M	$48M	-$8M
Q4 24	$96M	$66M	$9M
Q1 25	$87M	$58M	-$5M
Q2 25	$103M	$71M	$9M
Q3 25	$117M	$85M	-$3M
Q4 25	$121M	$79M	-$14M

Valuation

Quarter	P/S	P/E
Q1 22	3.2x	—
Q2 22	2.6x	—
Q3 22	1.6x	—
Q4 22	0.9x	—
Q1 23	1.3x	—
Q2 23	0.6x	—
Q3 23	0.5x	—
Q4 23	0.5x	—
Q1 24	1.1x	—
Q2 24	3.2x	—
Q3 24	4.3x	—
Q4 24	6.8x	—
Q1 25	7.7x	—
Q2 25	7.3x	1890.7x
Q3 25	8.2x	1575.1x
Q4 25	8.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$81M	-$85M
Q2 22	-$85M	-$88M
Q3 22	-$88M	-$93M
Q4 22	-$65M	-$67M
Q1 23	-$56M	-$56M
Q2 23	-$54M	-$56M
Q3 23	-$41M	-$41M
Q4 23	-$30M	-$32M
Q1 24	-$16M	-$17M
Q2 24	-$5M	-$6M
Q3 24	-$4M	-$5M
Q4 24	-$3M	-$6M
Q1 25	$10M	$4M
Q2 25	$10M	$8M
Q3 25	$16M	$10M
Q4 25	-$3M	-$7M

Capital Expenditures

Quarter	CapEx
Q1 22	$4M
Q2 22	$3M
Q3 22	$4M
Q4 22	$3M
Q1 23	$462.0K
Q2 23	$3M
Q3 23	$112.0K
Q4 23	$2M
Q1 24	$443.0K
Q2 24	$1M
Q3 24	$646.0K
Q4 24	$3M
Q1 25	$6M
Q2 25	$2M
Q3 25	$6M
Q4 25	$4M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+39.7%	+51.4%
Q2 22	-43.4%	+5.2%
Q3 22	+29.6%	-33.3%
Q4 22	+30.5%	+317.7%
Q1 23	-20.0%	-27.7%
Q2 23	+34.7%	-49.5%
Q3 23	-36.0%	-44.7%
Q4 23	-6.4%	-78.5%
Q1 24	+44.7%	-26.5%
Q2 24	+44.8%	-19.2%
Q3 24	+44.2%	-12.1%
Q4 24	+66.6%	+4.5%
Q1 25	+39.6%	+20.5%
Q2 25	+45.6%	+15.6%
Q3 25	+51.9%	+41.7%
Q4 25	+26.5%	+55.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$18M	32.6%
Q2 22	$23M	62.8%
Q3 22	$1M	1.5%
Q4 22	$422.0K	0.7%
Q1 23	$48.0K	0.1%
Q2 23	$108.0K	0.2%
Q3 23	$430.0K	0.8%
Q4 23	-$912.0K	-1.6%
Q1 24	-$451.0K	-0.7%
Q2 24	$3M	4.4%
Q3 24	$4M	4.7%
Q4 24	$3M	3.0%
Q1 25	$4M	4.6%
Q2 25	$8M	7.6%
Q3 25	$11M	9.1%
Q4 25	$10M	8.1%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$21M	$47M	$26M
Q2 22	$27M	$71M	$33M
Q3 22	$13M	$55M	$34M
Q4 22	$24M	$41M	$32M
Q1 23	$15M	$44M	$13M
Q2 23	$17M	$37M	$15M
Q3 23	$14M	$26M	$17M
Q4 23	$12M	$27M	$16M
Q1 24	$12M	$23M	$16M
Q2 24	$11M	$26M	$17M
Q3 24	$12M	$26M	$17M
Q4 24	$12M	$27M	$18M
Q1 25	$13M	$32M	$18M
Q2 25	$15M	$27M	$19M
Q3 25	$20M	$44M	$24M
Q4 25	$24M	$47M	$27M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$315M	$0	$315M
Q2 22	$285M	$0	$285M
Q3 22	$191M	$0	$191M
Q4 22	$137M	$0	$137M
Q1 23	$214M	$0	$214M
Q2 23	$157M	$0	$157M
Q3 23	$87M	$27M	$114M
Q4 23	$100M	$30M	$130M
Q1 24	$84M	$29M	$113M
Q2 24	$56M	$51M	$107M
Q3 24	$58M	$59M	$116M
Q4 24	$85M	$56M	$141M
Q1 25	$100M	$59M	$159M
Q2 25	$74M	$60M	$135M
Q3 25	$96M	$59M	$155M
Q4 25	$105M	$66M	$171M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	7M	+31.6%	+31.6%
Q2 22	10M	+38.2%	+81.9%
Q3 22	12M	+12.7%	+105.1%
Q4 22	12M	+2.0%	+109.2%
Q1 23	20M	+70.4%	+170.9%
Q2 23	25M	+26.7%	+148.3%
Q3 23	26M	+1.5%	+123.5%
Q4 23	26M	+0.7%	+120.7%
Q1 24	26M	+0.3%	+29.9%
Q2 24	27M	+2.1%	+4.7%
Q3 24	27M	+1.8%	+5.1%
Q4 24	27M	-0.4%	+3.9%
Q1 25	28M	+4.3%	+8.0%
Q2 25	30M	+5.7%	+11.8%
Q3 25	29M	-3.2%	+6.3%
Q4 25	27M	-6.6%	-0.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$95.6K	1K
Q1 25	$87.1K	1K
Q2 25	$102.7K	1K
Q3 25	$116.7K	1K
Q4 25	$93.1K	1K

Revenue / Employee